Abstract
AbstractINTRODUCTION: Chemo-radiotherapy (CRT) after maximal debulking surgery is the standard of care for patients with glioblastoma (GBM). This study reviews patient outcomes at our centre. Published data show worse outcomes for patients who present with GBM through AE 41% at 2 years. Improved OS was associated with ECOG performance status (PS=0 vs PS>0; p = 0.00212), type of surgery (biopsy vs partial/complete debulk; p<0.001), and age (<60yrs vs 60yrs; p<0.001). Strong but not statistically significant trends for OS were seen with MGMT status (methylated vs non-methylated; p = 0.053) and sex of patient, with females surviving longer (p = 0.14). 17 patients (13%) with IDH-1 mutation had a significantly improved OS (p=0.0432), with a median OS of 27 months. Patients who presented initially through AE once a GBM is large enough to become symptomatic, its outcomes are not predictable based on its size alone.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
